ANN ARBOR, Mich., May 06, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today reported financial results for the first quarter ended March 31, 2025, and provided a business update.

New guidelines have been developed for the monitoring of patients with inflammatory bowel disease in an effort to prevent them going on to ...

Discover why Mirum Pharmaceuticals is a growth opportunity with billion-dollar pipeline potentials, near-term catalysts, and ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Galmed Pharmaceuticals (GLMD), 6,307% surge in interest ...

Researchers and clinicians have developed major new guidelines for the monitoring of patients with inflammatory bowel disease ...

Abstracts include a presidential plenary-selected Phase 2 study evaluating the combination of obeticholic acid and ...